XBIO: Xenetic Bio Price to Sales

Brandmark of Xenetic Bio (XBIO)

The strong scientific team at Xenetic Biosciences (XBIO) minimizes financial risks, and the P/S market multiple visualizes this stability, where the 1.20 level captures recent values. Cost optimization is based on the full outsourcing of trials to external CROs, while high brand loyalty to XCART supports capitalization. This chart compares actual market demand with the company's revenue.

XBIO (Xenetic Biosciences) P/S Multiple history from 07/04/2022 to 11/17/2026

Analytical breakdowns for Xenetic Bio (XBIO)

General company analysis:XBIO (xeneticbio.com)
Brand item of Xenetic Biosciences Inc.

Assessing business resilience through the price-to-sales ratio allows an investor to determine the cost per unit of product created. Analyzing the smoothed P/S of Xenetic Biosciences (XBIO) reveals a critical dependence of the valuation on future successes, as the lack of current sales due to the preclinical status of developments renders this indicator extremely volatile and speculative.

Who Xenetic Biosciences competes with

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Revenue Ratio|Mural Oncology - P/S Multiple|KAPA - P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Revenue Ratio|Market Cap to Revenue CytoMed|Price-to-Revenue Ratio curis.com|Market Cap to Revenue Apollomics, Inc. (APLM)|P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Genprex GNPX|Price-to-Revenue Coefficient Calidi Bio (CLDI)|sunshinebiopharma.com - P/S Multiple|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd